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Aims. To evaluate the antidiabetic properties of borapetol B known as compound 1 (C1) isolated from Tinospora crispa in
normoglycemic controlWistar (W) and spontaneously type 2 diabetic Goto-Kakizaki (GK) rats.Methods.The effect of C1 on blood
glucose and plasma insulin was assessed by an oral glucose tolerance test.The effect of C1 on insulin secretion was assessed by batch
incubation and perifusion experiments using isolated pancreatic islets. Results. An acute oral administration of C1 improved blood
glucose levels in treated versus placebo groups with areas under glucose curves 0–120min being 72 ± 17 versus 344 ± 10mmol/L
(𝑃 < 0.001) and 492±63 versus 862±55mmol/L (𝑃 < 0.01) inW and GK rats, respectively. Plasma insulin levels were increased by
2-fold in treated W and GK rats versus placebo group at 30min (𝑃 < 0.05). C1 dose-dependently increased insulin secretion from
W and GK isolated islets at 3.3mM and 16.7mM glucose. The perifusions of isolated islets indicated that C1 did not cause leakage
of insulin by damaging islet beta cells (𝑃 < 0.001). Conclusion. This study provides evidence that borapetol B (C1) has antidiabetic
properties mainly due to its stimulation of insulin release.
1. Introduction
Type 2 diabetes mellitus is a heterogeneous disorder asso-
ciated with impaired insulin secretion from pancreatic 𝛽-
cells and decreased insulin sensitivity which leads to hyper-
glycemia [1, 2].
The drugs that are currently available in the treatment of
diabetes are mainly targeted either to improve insulin sensi-
tivity or improve insulin secretion or both. Even after the dis-
covery and use of insulin and availability of existing modern
antidiabetic agents such as sulphonylureas, biguanides, and
incretins, the search of more effective drugs of plant origin
for the treatment of diabetes continues as an alternative [3–6].
Several medicinal plant parts have demonstrated promising
results in terms of achieving normoglycemia by improving
insulin secretion from pancreatic beta cells, while some have
shown to increase peripheral utilization of glucose [7, 8] or
improve hepatic insulin sensitivity [9–11].
Tinospora crispa (T. crispa) belongs to the Menisperma-
ceae plant family and is known by various vernacular names
such as “Akar patawali” or “Akar seruntum” (Malays). It
comprises a climbing vine found throughout the southwest-
ern part of China to southeast Asia including Malaysia. The
aqueous extract ofT. crispa is used in traditionalmedicine for
treatment of type 2 diabetes [12, 13].The antidiabetic effects of
T. crispa extract have been previously demonstrated both in
vivo and in vitro [12–16]. In this study, we have investigated
the antidiabetic effect of borapetol B (C1), a compound
isolated from T. crispa by evaluating the blood glucose
levels and stimulation of insulin secretion in normoglycemic
controlWistar (W) and diabetic Goto-Kakizaki (GK) rats, an
animal model of type 2 diabetes [17].
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2. Materials and Methods
2.1. Animals. Male normoglycemic control Wistar (W) and
spontaneously type 2 diabetic Goto-Kakizaki (GK) rats (200–
350 g) were used in this study. GK rats, originating from W
rats, were bred in our department [17].W rats were purchased
from a commercial breeder (Charles River).The animals were
kept at 22∘C with an alternating 12-hour light-dark cycle
(6 am–6 pm) and were allowed access to food and water
before being anesthetized for isolation of pancreatic islets.
The study was approved by the Laboratory Animal Ethics
Committee of the Karolinska Institutet.
2.2. Plant Material. T. crispa vines were collected in Kota
Belud (Sabah,Malaysia) inMay 2005, identified by Berhaman
Ahmad (Universiti Malaysia Sabah) and voucher speci-
men (FRI54832) deposited at the Forest Research Institute
Malaysia. The stems were cleaned, air dried (3 days), and
ground into coarse powder. Stem powder was sealed and
stored at 4∘C in a dry cabinet.
2.3. Bioassay-Guided Isolation of Borapetol B. Isolation and
purification of borapetol B (C1) from T. crispa were modified
from a previous study [18]. During the isolation procedure,
fractions stimulating insulin secretion in a bioassay with
isolated pancreatic islets from W rats were selected for
subsequent purification [17].
The stem powder (5 kg) was extracted by sonicating with
solvents at room temperature (25∘C) for 15 minutes. It was
first defatted with hexane (20 L) followed by methanol-water
(4 : 1 by volume, 20 L) solvent extraction. Each extraction was
repeated 3 times. Extracts were consolidated and reduced to
one-third volume by vacuum evaporation yielding a brown
syrup. The syrup was acidified to pH 2 with sulphuric
acid (50% v/v) and partitioned four times with chloroform.
The chloroform layer was evaporated to dryness to obtain
brownish mass which showed prominent insulin stimulatory
effect.
The brown mass was chromatographed over normal
phase silica gel eluted with 100% chloroform followed by
chloroform methanol (9.5 : 0.5) and subsequently increasing
eluent polarity with methanol. Chromatographic fractions
were monitored by thin layer chromatography (TLC) visu-
alized at 365 nm. Fractions containing spots possessing 𝑅
𝑓
value within the range of 0.20–0.75 (chloroform methanol
9.5 : 0.5) were examined further as these fractions were also
inducing insulin secretion.
These fractions were consolidated and re-chromato-
graphed to yield 10 subfractions.When cooled (4∘C), subfrac-
tions seven and eight yielded colourless, monoclinic crystals.
Upon recrystallization with chloroform-methanol, crystals
(450mg) were recovered by vacuum filtration and washed
with cold chloroform. TLC revealed a single compound
known as C1 (Figure 1) which stimulated insulin secretion.
The identity of C1 as borapetol B was further confirmed using
1H-NMR [18, 19].
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Figure 1: Chemical structure of C1 or borapetol B isolated from T.
crispa.
2.4. Study Design. The protocol of this study is presented
in Figure 2. The effect of C1 on the blood glucose and
plasma insulin was assessed by an oral glucose tolerance
test in normoglycemic control W and GK rats. For in vitro
studies, the stimulation of insulin secretion was assessed
by performing batch incubation and perifusion experiments
using isolated W and GK pancreatic islets.
2.4.1. Oral Glucose Tolerance Test (OGTT). An OGTT was
performed to identify the effect of C1 on the blood glucose
levels in W and GK rats. The same rats (𝑛 = 5) were
used for both control (placebo) and treatment groups with
7 days between each type of treatment. The rats were fasted
overnight (14-15 hours), allowing access only to plain drink-
ing water. For the treatment group, 10 𝜇g/100 g body weight
of C1 was administrated orally by gavage 30min prior to
an oral glucose challenge (0.2 g/100 g body weight). Control
rats were given water only. Blood for glucose determination
was measured by tail-prick method at different time points:
−30min (before the administration of the compound), 0min
(before glucose load), then at 30, 60, and 120min after
glucose administration. Blood glucose level was measured
using a glucometer, Accu-check Aviva (Roche Diagnostic
GmbH, USA). Blood samples were also collected for the
measurement of plasma insulin levels (about 20 𝜇L/serum
sample) at 0 and 30min.
2.4.2. Isolation of Pancreatic Islets. Islets fromW and GK rats
were used for in vitro experiments. The isolation of islets was
performed using collagenase digestion method. Hank’s bal-
anced salt solution (HBBS) (Statensveterina¨ranstalt, Sweden)
containing collagenase (Sigma-Aldrich, USA) was injected
through the bile duct. For W and GK rats, 9mg and 24mg
of collagenase were added to 10mL of HBBS, respectively.
The pancreas was then collected, incubated in 37∘C water
bath without shaking for 24min, followed by several washing
and centrifugation steps withHBBS, Histopaque 1119 (Sigma-
Aldrich, USA), and Histopaque 1077 (Sigma-Aldrich, USA).
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Figure 2: Study design. The in vivo and in vitro studies were carried out to identify the effects of T. crispa C1 in W and GK rats.
The islets were hand-picked under a stereomicroscope and
then cultured for 24 hours at 37∘C, with an atmosphere of 5%
CO
2
-95% air in RPMI 1640 culture medium (SVA, Swe-
den) supplemented with 30mg L-glutamine (Sigma-Aldrich,
USA), 11mM glucose (Sigma-Aldrich, USA), and antibiotics
(100 IU/mL penicillin and 0.1mg/mL streptomycin) (Invitro-
gen, USA). Heat-inactivated fetal calf serum (10%) was added
to RPMI 1640 medium before the incubation of islets [17].
2.4.3. Batch Incubations for Insulin Secretion. The medium
used was Krebs-Ringer bicarbonate (KRB) buffer solution
[20] containing 10mmol/L HEPES (Sigma-Aldrich, USA)
and 0.2% bovine serum albumin. Following overnight incu-
bation, the islets were preincubated at 3.3mM glucose for
30–45min at 37∘C with an atmosphere of 5% CO
2
-95%
air. After washing islets twice with the incubation medium,
batches of 3 islets of similar size were incubated at 3.3mM or
16.7mM glucose with or without C1 compound at different
concentrations (0.1, 1, and 10 𝜇g/mL). The tubes containing
islets and solutions were then incubated for 60min in 37∘C
waterbath, slowly shaking. After incubation, 200𝜇L of the
solutions was transferred to new tubes for RIA and kept in
freezer −20∘C until being assayed for insulin by RIA.
2.4.4. Perifusions of Islets. Perifusions of islets were done to
investigate how C1 affects the kinetics of insulin release [20].
Batches of 30 or 50 isolated W and GK rat islets each were
layered between polystyrene beads (Bio-Rad Laboratories,
Inc., USA) in a perifusion chamber and perifused by use
of peristaltic pump (Ismatec SA, Zurich, Switzerland) as
previously described [21]. Perifusion medium was collected
in fractions every 2min to establish the basal insulin secretion
rate at 3.3mM glucose for 20min (−20 to min 0). At min 0
to 15, the glucose concentration was maintained at 3.3mM
glucose and increased to 16.7mM glucose at 15 to 30min.
Finally, the glucose concentration was then switched back
to 3.3mM glucose. C1 (10 𝜇g/mL) was added at min 0–15
in 3.3mM glucose and at min 15–30 in 16.7mM glucose.
The fractions were collected and stored in −20∘C for insulin
radioimmunoassay (RIA).
2.5. Insulin RIA. Aliquots obtained from batch incubations
and perifusions experiments were analyzed for insulin con-
tent using RIA [22].
2.6. Statistical Analysis. The results are presented as mean ±
SEM. Difference between experimental groups was analyzed
using paired t-test for OGTT and insulin secretion experi-
ments whereas 2-way ANOVA was used for perifusions of
islet experiment. 𝑃 value of less than 0.05 was considered to
be significant. All data were analyzed using Prism Graph Pad
Software (CA, USA).
3. Results
3.1. Oral Glucose Tolerance Test (OGTT) in W and GK Rats.
After the oral administration of glucose, the blood glucose
levels reached a peak at 30 minutes and then gradually
decreased in bothWandGKrats. InWrats, the blood glucose
levels at 30, 60, and 120min were significantly decreased
in the treated group as compared to the placebo group (at
120min 4.7 ± 0.1 versus 6.1 ± 0.4 to mmol/L; 𝑃 < 0.01)
(Figure 3(a)) andwith areas under the glucose curves (AUCs)
(0min to 120min) being 72 ± 17 versus 344 ± 10mmol/L
(𝑃 < 0.001) (Figure 3(b)). In GK rats, the blood glucose levels
at 60 and 120min were significantly decreased in the treated
group as compared to the placebo group (at 120min 12.5 ± 0.8
versus 15.3 ± 0.9 mmol/L;𝑃 < 0.05) (Figure 4(a)) with AUCs
(0–120min) being 492 ± 63 versus 862 ± 55mmol/L (𝑃 <
0.01) (Figure 4(b)). In W and GK rats, plasma insulin levels
were increased from 0min to 30min in both placebo and
treated groups (Figures 5 and 6) and there was a significant
difference observed between the placebo and treated groups
at 30 min (𝑃 < 0.05). In W rat, the mean values for plasma
insulin in the treated and placebo groups at 0min were 18 ±
4 𝜇U/mL versus 10 ± 1 𝜇U/mL respectively and at 30min,
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Figure 3: (a) Blood glucose level in the oral glucose tolerance test in
W rats. 10𝜇g/100 g of b.w. of T. crispa C1 (- - -) or placebo (—) was
given orally 30 minutes prior to the glucose challenge (0.2 g/100 g
of b.w.). Data are presented as means ± SEM (𝑛 = 5). ∗∗𝑃 < 0.01
versus placebo; ∗∗∗𝑃 < 0.001 versus placebo. (b) Area under the
glucose curve in the oral glucose tolerance test in W rats. Data are
presented as means ± SEM (𝑛 = 5). ∗∗∗𝑃 < 0.001 versus placebo
61 ± 9 𝜇U/mL versus 27 ± 4 𝜇U/mL (𝑃 < 0.05), respectively
(Figure 5). In GK, the mean values for plasma insulin in
the treated and placebo groups at 0min were 18 ± 4 𝜇U/mL
versus 11 ± 1𝜇U/mL and at 30min, 64 ± 8 𝜇U/mL versus 30 ±
4 𝜇U/mL (𝑃 < 0.05), respectively (Figure 6).
3.2. Effects of C1 on Insulin Secretion of W Rat Islets and GK
Rat Islets. In W rat islets, the incubation of islets with C1 at
0.1, 1, and 10 𝜇g/mL in 3.3mM glucose significantly increased
the insulin secretion 6.3-fold (𝑃 < 0.01), 8.1-fold (𝑃 <
0.05) and 9.1-fold (𝑃 < 0.001), respectively, compared to the
control group (Table 1). At 16.7mM glucose concentration,
C1 (0.1, 1, and 10 𝜇g/mL) stimulated insulin secretion 1.5-fold
(𝑃 < 0.05), 1.9-fold (𝑃 < 0.05), and 5.0-fold (𝑃 < 0.001),
respectively, compared to the control group. The incubation
of GK rat islets with C1 at 0.1, 1, and 10 𝜇g/mL in 3.3mM
glucose significantly increased the insulin secretion 3.9-fold,
6.3-fold and 8.8-fold (all 𝑃 < 0.05), respectively, compared
Table 1: The effect of different concentrations of T. crispa C1 at low
(3.3mM) and high (16.7mM) glucose on insulin secretion from W
(𝑛 = 5) and GK (𝑛 = 3) rat islets.
Addition to incubation medium Insulin release (𝜇U/islet/h)
Glucose (mM) T. crispa C1(𝜇g/mL) W islets GK islets
3.3
None 2.4 ± 0.1 1.2 ± 0.2
0.1 15.1 ± 2.2∗∗ 4.7 ± 0.3∗
1 19.5 ± 4∗ 7.5 ± 0.9∗
10 21.9 ± 2∗∗∗ 10.5 ± 1.8∗
16.7
None 32.5 ± 1.8 13.6 ± 0.6
0.1 48.8 ± 6# 20.6 ± 1.1#
1 63.1 ± 8.9# 30.9 ± 3.8#
10 164.5 ± 11.3### 57.3 ± 6.3#
Data are presented as means ± SEM. W: ∗𝑃 < 0.05 versus 3.3mM glucose;
∗∗
𝑃 < 0.01 versus 3.3mM glucose; ∗∗∗𝑃 < 0.001 versus 3.3mM glucose;
#
𝑃 < 0.05 versus 16.7mM glucose; ###𝑃 < 0.001 versus 16.7mM glucose GK:
∗
𝑃 < 0.05 versus 3.3mM glucose; #𝑃 < 0.05 versus 16.7mM glucose.
to the control group. At 16.7mM glucose, C1 at 0.1, 1, and
10 𝜇g/mL stimulated insulin release 1.5-fold, 2.3-fold, and 4.2-
fold (all 𝑃 < 0.05), respectively, compared to the control
group.
3.3. Kinetics of Insulin Secretion of Isolated Islets. Insulin
secretion was increased as 10 𝜇g/mL of C1 was added to
perifusate containing 3.3mM (0–16min) and 16.7mM (16–
30min) glucose in both W (Figure 7) and GK (Figure 8) rat
islets. In W, the addition of C1 stimulated insulin secretion
by 5.5-fold from 0.2 ± 0.01 𝜇U/islet/min (0min) to 1.1 ±
0.16 𝜇U/islet/min (12min) and further increased to 7.5-fold
(1.5 ± 0.16 𝜇U/islet/min) (22min). There was a significant
difference observed from 2min to 32min (𝑃 < 0.001) in
the treated group compared to control (Figure 7). In GK
rat, C1 stimulated insulin secretion by 2.5-fold from 0.17 ±
0.03 𝜇U/islet/min (0min) to 0.43±0.05 𝜇U/islet/min (2min)
(𝑃 < 0.001). The insulin secretion was increased to 0.8 ±
0.03 𝜇U/islet/min (20min) (𝑃 < 0.001) in 16.7mM glucose.
There was a significant difference observed between the
treated and control group at 2 to 4min (𝑃 < 0.001) and
between 20 to 30min (𝑃 < 0.001) (Figure 8). The insulin
secretion returned to basal level in both W and GK when C1
was omitted from the perifusate.
4. Discussion
We show that oral administration of T. crispa C1 30 minute
before an oral glucose challenge significantly decreased blood
glucose levels in W rats. This was most likely mediated
through enhanced insulin secretion, since the plasma insulin
level in treated W rats increased by 2-fold compared to the
placebo group. This is further supported by our findings that
C1 stimulates insulin secretion from isolated pancreatic islets,
both in batch incubations and in perifusions.
A major defect behind type 2 diabetes is inadequate
insulin secretion, that would be needed to compensate
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Figure 4: (a) Blood glucose level in the oral glucose tolerance test in GK rats. 10 𝜇g/100 g of b.w of T. crispaC1 (- - -) or placebo (—) was given
orally 30 minutes prior to the glucose challenge (0.2 g/100 g of b.w.). Data are presented as means ± SEM (𝑛 = 5). ∗𝑃 < 0.05 versus placebo.
(b) Area under the glucose curve in the oral glucose tolerance test in GK rats. Data are presented as means ± SEM (𝑛 = 5). ∗∗𝑃 < 0.01 versus
placebo.
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Figure 5: Plasma insulin level at 0 and 30min in the oral glucose
tolerance test fromW rats. Data are presented as means ± SEM (𝑛 =
5). T. crispa C1 (◼) or placebo (◻). ∗∗𝑃 < 0.01 versus 0min (placebo
and T. crispa C1, resp.); #𝑃 < 0.05 versus 30min (placebo).
for decreased insulin sensitivity [1, 2]. This in turn leads
to development of hyperglycemia. To further assess the
insulinotropic properties of C1 in type 2 diabetes, studieswere
performed in spontaneously diabetic Goto-Kakizaki (GK)
rats. The GK rat strain was established from normoglycemic
W rats by repeated inbreeding in each successive generation
of the siblings with the highest blood glucose levels during an
OGTT [23]. GK rats are lean and developmild hyperglycemia
early in life due to impaired insulin secretion, in particular
a consistently low insulin response to glucose stimulation
[17, 24]. Impaired glucose-stimulated insulin secretion has
been demonstrated in vivo, in the perifused isolated pancreas
and in isolated pancreatic islets of GK rats [24].
We now demonstrated that oral treatment with C1
decreased blood glucose levels in parallel with an increase in
plasma insulin levels during the OGTT, not only in W rats
but also in GK rats. In addition, C1 at different concentrations
increased insulin release from GK rat islets in low and high
glucose and the stimulatory effect was observed in a dose-
dependent manner. In the perifusions of islets experiment,
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Figure 6: Plasma insulin level at 0 and 30min in the oral glucose
tolerance test fromGK rats. Data are presented asmeans± SEM (𝑛 =
5). T. crispa C1 (◼) or placebo (◻). ∗𝑃 < 0.05 versus 0 min (placebo);
∗∗
𝑃 < 0.01 versus 0 min (T. crispa C1); #𝑃 < 0.05 versus 30min
(placebo).
C1 stimulated insulin secretion in both W and GK rat islets.
The insulin secretion gradually returned to basal level on the
removal of C1, supporting that C1 did not cause nonspecific
insulin leakage by damaging islets beta cells.
Previous findings have shown the effectiveness of extract
and isolated compounds from T. crispa in the stimulation of
insulin release and insulin sensitivity in normal and diabetic
animal models [12, 14]. A two-week treatment with T. crispa
extract significantly reduced the blood glucose level and
caused a significant increase in plasma insulin in moderately
diabetic rats with some functional 𝛽-cells. No effect was
observed in severely diabetic animals suggesting that the
hypoglycemic effect of T. crispa extract was not due to extra
pancreatic action but through the stimulation of insulin
secretion [13].
An in vitro study showed that T. crispa extract induced a
dosage-dependent stimulation and also potentiated basal and
glucose-stimulated secretion of insulin in rat islets and HIT-
T15 cells. The insulin secretion in perifused isolated human
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Figure 7: Effect of T. crispa C1 on kinetics of insulin secretion of W rat islets. Data are presented as means ± SEM from six separate
experiments. Aliquots of the medium were collected and then determined by RIA. T. crispa C1 (- - -) or control (—). ∗∗∗𝑃 < 0.001 versus
control.
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Figure 8: Effect of T. crispa C1 on kinetics of insulin secretion of GK rat islets. Data are presented as means ± SEM from three separate
experiments. Aliquots of the medium were collected and then determined by RIA. T. crispa C1 (- - -) or control (—). ∗∗∗𝑃 < 0.001 versus
control.
and rat islets as well as HIT-T15 𝛽 cells returned to basal levels
as T. crispa extract was omitted from perifusate indicating
that the insulintropic activity was not due to toxicity effect
[14].
Another compound isolated from T. crispa borapetoside
C reduced plasma glucose levels in normal and type 2
diabeticmice and streptozotocin induced type 1 diabeticmice
but increased plasma insulin levels in normal and type 2
diabetic mice only. The hypoglycemic effect was associated
with increase of glucose utilization in peripheral tissues and
the reduction of hepatic gluconeogenesis [15]. In another
study, borapetoside C increased glucose utilization, delayed
the development of insulin resistance, and enhanced insulin
sensitivity in diabetic mice [16].
It would have been interesting to explore the anti-diabetic
effects of borapetoside C with borapetol B (C1) and to
compare with the effects of C1 in W and GK rats. Since
GK rats in addition to defective insulin secretion display
decreased insulin sensitivity, it is possible that a stronger
antidiabetic effect would be obtained by treatment with
Evidence-Based Complementary and Alternative Medicine 7
a combination of C1 and borapetoside C. However, due to
limitations and difficulties to obtain borapetoside B, we have
focused on the effects of C1.
5. Conclusion
We demonstrate that T. crispa C1 improves the diabetic
condition inGK rats by stimulating insulin secretion. Further
studies are needed to understand the mechanisms involved
by which T. crispa C1 induces insulin release from pancreatic
islets.
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